Navigation Links
Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma
Date:7/24/2014

BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). EU5 pulmonologists expect robust uptake of Relvar as a first-line LABA/ICS FDC in the treatment of asthma with one-quarter to half of surveyed pulmonologists considering the drug as a first-line maintenance therapy for treatment-naive persistent asthma patients. However, interviewed payers across EU5 countries caution that in order for Relvar to secure premium pricing, superior efficacy data over Seretide (GlaxoSmithKline) would be required. Thus, despite its lower dosing frequency, the existing noninferiority data for Relvar will most likely drive an equivalent price to that of currently available twice-daily LABA/ICS FDCs.

Other key findings from the European Physician and Payer Forum report entitled Asthma in the EU5: What Are the Expectations for Optimal Positioning of New and Emerging Inhaled and Biological Therapies in Market Access Systems?:

  • Market-access hurdles for emerging biologics: Interviewed payers and surveyed pulmonologists across the EU5 view the ability to identify likely responders as a benefit for the emerging anti-IL-5 therapies -- Cinquil (Cephalon/Teva), Bosatria (GlaxoSmithKline) and benralizumab (MedImmune/AstraZeneca). However, payers anticipate the cost of such diagnostic testing could be a hurdle for reimbursement and uptake.
  • Impact
    '/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... new understanding of,the role played by the protein ... novel therapies to rebuild muscle tissue,damaged by disease, ... Institute for Cancer Research and Molecular Medicine at ... The researchers reported their findings, "Cdk9-55: A ...
... implantable,medical device, developed in collaboration with Mayo Clinic ... alternative to existing,bariatric surgeries, according to findings published ... In a six-month open label trial involving three ... obese participants who received the,vagal nerve blocking device, ...
Cached Medicine Technology:International Team Locates Key Player in Muscle Regeneration 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... Dallas, TX (PRWEB) December 26, 2014 The ... covered in this report. In 2013, GlobalData’s forecast estimates that ... the largest CRC market due to the high incidence of ... compared with the 5EU, Japan, and China. Increased sales of ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , FAIRFIELD, N.J., Sept. 22 ... today at the Transcatheter Cardiovascular Therapeutics (TCT) convention in San ... cleared the company,s MEGA(TM) 8Fr. 50cc intra-aortic balloon (IAB) ... 8Fr. shaft, the MEGA has a smaller insertion point than ...
... of the H1N1 influenza pandemic could present a host ... advance, according to the University of Toronto Joint Centre ... discussion. Topics include duty of health care workers ... on individual freedoms and privacy and their responsibilities administering ...
... , DETROIT, Sept. 23 Caraco ... on September 20, 2009, Georges Ugeux resigned as a director of ... the Board. Mr. Ugeux was the chairman of the independent committee. ... indicated that he had disagreements with the majority shareholder and senior ...
... , , Former Vermont ... , BURLINGTON, Vt., Sept. 23 -- Governor Howard Dean will ... to discuss health care reform and sign copies of his new book, ... Dean will appear at the Philadelphia Free Library for a ...
... NEW YORK, Sept. 23 The Michael J. Fox Foundation ... translate neurotrophic factor advances from pre-clinical and early-phase clinical work ... will be awarded under a new Directed LEAPS (Linked ... , The Foundation,s intention is to identify and ...
... SCOTTSDALE, Ariz., Sept. 23 Seventh and eighth graders ... experienced firsthand some of the challenges that come with aging. ... the not-for-profit SCAN Health Plan Arizona, the students participated in ... the physical challenges facing seniors. , , ...
Cached Medicine News:Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 2Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 3Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 2Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 3Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 4Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 5Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 6Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 7Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 8Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 9Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 3Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2Health News:Twelve Going on 70: SCAN Health Plan Arizona Helps 7th and 8th Graders Understand Aging With Senior Sensitivity Training 2
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
Medicine Products: